Cornerstone Pharmaceuticals: Phase II clinical trial application for CS2009 approved by the U.S. FDA.

On February 16th, cornerstone pharmaceuticals announced on the Hong Kong Stock Exchange that the company's core asset CS2009, used for phase II clinical trials of new drugs for advanced solid tumors, has been approved by the US Food and Drug Administration. The approval of the phase II IND application for CS2009 for advanced solid tumors by the FDA marks an important milestone in the global development of this innovative immunotherapy.